Drug Search Results
Using advanced filters...
Advanced Search [+]

Fermagate

Alternative Names: fermagate
Clinical Status: Inactive
Latest Update: 2010-10-19
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Inorganic Phosphate Binder

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Ineos Healthcare Limited
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Kidney Failure, Chronic|Hyperphosphatemia

Phase 2: Hyperphosphatemia|Kidney Failure, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

ALCON

P2

Terminated

Kidney Failure, Chronic

2008-05-01

2019-03-21

Treatments

ACT3

P2

Completed

Kidney Failure, Chronic|Hyperphosphatemia

2008-01-01

2019-03-21

Treatments

IH 001 (ACT 2)

P2

Completed

Hyperphosphatemia|Kidney Failure, Chronic

2007-06-01

2019-03-21

Treatments

ACT 402

P3

Terminated

Hyperphosphatemia|Kidney Failure, Chronic

2011-09-01

2019-03-18

2008-004729-41

P3

Completed

Hyperphosphatemia

2011-07-27

2022-03-12

Treatments

2008-004730-25

P3

Terminated

Unknown

2010-03-31

2022-03-12

Treatments

Recent News Events

Date

Type

Title